Novartis Raises 2026 Profit Forecast After Q3 Sales Rise 4% to $14.52 Billion
Novartis (NYSE:NVS) reported Q3 revenue of $14.52B, up 4%, and raised its 2026 core operating income forecast. Sales of Kisqali, Kesimpta, Scemblix, and Leqvio drove growth, while a $1.9B impairment charge impacted reported earnings. The company expects core operating income to be in line with 2025 or increase slightly.
How this was made
The 30-second read
Why it matters
The guidance upgrade outweighs the earnings hit, likely prompting a modest stock rally.
Market read
First‑report earnings and guidance lift for a large‑cap pharma, relevant for sector and global markets.
What to watch
Potential regulatory delays for remibrutinib and the $1.9 bn del‑desiran impairment may temper enthusiasm.
Background
Novartis reported Q3 revenue of $14.52 bn, core operating income up 11%, but statutory earnings fell due to a $1.9 bn impairment.
Ticker impact
Novartis raised its full-year 2026 core operating income guidance after Q3 sales rose 4% and margins improved.
upward pressure as investors price in stronger profit outlook
The new guidance moves from a low single‑digit decline to flat or low‑single‑digit growth, a material shift for a large‑cap pharma.
Market effects
May lift broader healthcare and pharma sector sentiment on earnings resilience.
Positive for European markets where many pharma stocks are listed.
Adds to global growth narrative for large‑cap biotech/pharma firms.
Counterpoint
The impairment charge and ongoing generic competition could still weigh on margins, limiting upside.
Key entities
- companyNovartis AG
Swiss pharmaceutical group issuing the earnings and guidance update.
